We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
RNAi hype turns to hope.
- Authors
Dorey, Emma
- Abstract
The article reports on the increased number of patent applications for ribonucleic acid interference (RNAi). RNAi involves synthesizing double-stranded RNA molecules which effectively silence faulty genes which cause many diseases. Partner at Marks and Clerk Gareth Williams said that the patent explosion of RNAi is a fair standard for something that is promising. The two front runners, Alnylam Pharmaceuticals and Sirna Therapeutics, announced the positive phase I data for RNAi therapeutics for respiratory syncytial virus and macular degeneration.
- Subjects
GENE silencing; RNA synthesis; PATENTS; WILLIAMS, Gareth; ALNYLAM Pharmaceuticals Inc.; SIRNA Therapeutics Inc.
- Publication
Chemistry & Industry, 2006, Issue 10, p6
- ISSN
0009-3068
- Publication type
Article